OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
AXAF58

AXA SA

Life & Health InsuranceVerified

AXA SA's capital structure is characterized by a lack of dilution risk, as shares outstanding for both basic and diluted scenarios are identical at 2.06 billion shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's valuation snapshot is currently unavailable, but its price targets suggest a range of 40.00 EUR to 50.70 EUR, with a mean of 45.97 EUR and a median of 46.82 EUR. Profitability and returns are not currently quantifiable due to the absence of valuation snapshot data. However, as a life and health insurer, AXA's performance is typically measured by metrics such as combined ratio, underwriting margin, and investment yield. These metrics are not provided in the current dataset, so a direct comparison to industry medians is not possible. AXA's revenue is derived from its global operations, but the specific geographic and segment breakdown is not disclosed in the available data. The company operates in a highly regulated and competitive environment, and its exposure to regional markets is likely significant, though the exact concentration is not quantified in the input data. Growth trajectory is not explicitly outlined in the input data, but analyst price targets suggest a relatively stable outlook. The mean recommendation of 1.91 indicates a slight bias toward positive sentiment, with 5 strong-buy and 14 buy ratings. No specific revenue history or growth rates are provided to support a more detailed growth narrative. Risk factors include the inability to assess liquidity risk, which is a concern for any financial institution. The company is also exposed to regulatory and market risks inherent to the insurance industry, such as claims volatility and interest rate sensitivity. Dilution risk is currently low, as no dilution potential is reported in the data. Recent events, such as filings or transcripts, are not included in the input data, so no specific recent developments can be cited. Analysts' price targets and recommendations are the most recent signals of market sentiment.

30-day price · AXAF-0.99 (-2.5%)
Low$38.67High$42.87Close$39.18As of17 May, 00:00 UTC
Profile
CompanyAXA SA
TickerAXAF.PA
SectorFinancials
BusinessInsurance
Industry groupInsurance
IndustryLife & Health Insurance
AI analysis

Business. AXA SA is a multinational insurance company that provides life and health insurance products, generating revenue through premium income and investment returns.

Classification. AXA is classified under the Financials sector, specifically in the Insurance industry, with a high confidence level of 0.92 based on verified market data.

AXA SA's capital structure is characterized by a lack of dilution risk, as shares outstanding for both basic and diluted scenarios are identical at 2.06 billion shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's valuation snapshot is currently unavailable, but its price targets suggest a range of 40.00 EUR to 50.70 EUR, with a mean of 45.97 EUR and a median of 46.82 EUR. Profitability and returns are not currently quantifiable due to the absence of valuation snapshot data. However, as a life and health insurer, AXA's performance is typically measured by metrics such as combined ratio, underwriting margin, and investment yield. These metrics are not provided in the current dataset, so a direct comparison to industry medians is not possible. AXA's revenue is derived from its global operations, but the specific geographic and segment breakdown is not disclosed in the available data. The company operates in a highly regulated and competitive environment, and its exposure to regional markets is likely significant, though the exact concentration is not quantified in the input data. Growth trajectory is not explicitly outlined in the input data, but analyst price targets suggest a relatively stable outlook. The mean recommendation of 1.91 indicates a slight bias toward positive sentiment, with 5 strong-buy and 14 buy ratings. No specific revenue history or growth rates are provided to support a more detailed growth narrative. Risk factors include the inability to assess liquidity risk, which is a concern for any financial institution. The company is also exposed to regulatory and market risks inherent to the insurance industry, such as claims volatility and interest rate sensitivity. Dilution risk is currently low, as no dilution potential is reported in the data. Recent events, such as filings or transcripts, are not included in the input data, so no specific recent developments can be cited. Analysts' price targets and recommendations are the most recent signals of market sentiment.
Key takeaways
  • AXA SA has no dilution risk as of the latest data, with basic and diluted shares outstanding being equal.
  • Analysts have a generally positive outlook, with a mean recommendation of 1.91 and a median price target of 46.82 EUR.
  • Liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents.
  • The company's profitability and returns are not currently quantifiable due to the absence of valuation snapshot data.
  • AXA's geographic and segment revenue concentration is not disclosed in the available data.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$8.27B$7.29B$4.54B
FY-3$7.38B$5.06B
FY-2$8.80B$7.19B
FY-1$10.41B$7.89B
FY0$10.37B$9.80B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$775.49B$71.14B$25.05B
FY-3$638.36B$46.07B$26.17B
FY-2$644.38B$49.58B$25.38B
FY-1$653.76B$49.94B$18.99B
FY0$635.54B$47.17B$22.25B
PeriodOCFCapExFCFSBC
FY-4$9.94B-$350.0M$4.54B
FY-3$8.22B-$398.0M
FY-2$3.94B-$419.0M
FY-1$12.47B-$476.0M
FY0$22.35B-$428.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Life & Health Insurance · cohort 15 companies
MetricAXAFActivity
Op margin12.3% medp25 5.6% · p75 21.6%
Net margin2.9% medp25 0.5% · p75 10.1%
Gross margin28.2% medp25 13.4% · p75 30.5%
CapEx / revenue-2.1% medp25 -8.2% · p75 -1.2%
Debt / equity27.5% medp25 4.7% · p75 66.5%
Observations
IR observations
Mean price target45.97 EUR
Median price target46.82 EUR
High price target50.70 EUR
Low price target40.00 EUR
Mean recommendation1.91 (1=strong buy, 5=strong sell)
Strong-buy count5.00
Buy count14.00
Hold count3.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate4.16 EUR
Last actual EPS3.86 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-01 03:35 UTC#17b0bff2
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 10:43 UTCJob: 22256818